With the validation of the SARS-CoV-2 mRNA vaccines on the global stage, mRNA vaccines and therapeutics are taking the front seat of many biopharma development pipelines. There is an ever-increasing ...

The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

mRNA vaccines are a cornerstone of modern healthcare – and this has perhaps never been more true than in the last two years. An essential methodology supporting the fight against the COVID-19 pandemic ...

As the COVID-19 pandemic began to wreak havoc on the world in 2020, the biopharmaceutical industry started working tirelessly to develop a vaccine to stop this global threat. Emerging from this effort ...

With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is hindered by its production ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...

mRNA innovation is one of the most exciting and impactful areas of healthcare globally today. A process that has increasingly expansive application potential in treating diseases or functioning as a ...

Biopharma has been quickly ramping up investment in messenger RNA (mRNA), the defining technology behind the Moderna and Pfizer-BioNTech SARS-CoV-2 vaccines. With big plans for mRNA-based therapies, ...

STONY BROOK, N.Y. & TORONTO--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), ...